Terence J. Purdon

5.7k citations

41 papers · 3.1k indexed · 1 hit paper · h-index 22

Co-authors: Renier J. Brentjens Mythili Koneru David R. Spriggs Oladapo Yeku Dayenne G. van Leeuwen Anthony F. Daniyan Kevin J. Curran Sarwish Rafiq
Topics: CAR-T cell therapy research (40 papers)Immune Cell Function and Interaction (11 papers)Viral Infectious Diseases and Gene Expression in Insects (8 papers)
Cited by: Oncology Immunology Genetics
Journals: Nature Communications Journal of Clinical Oncology Blood
Partner nations: United States Switzerland Netherlands

In The Last Decade

Terence J. Purdon

41 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

2018 628 citations Sarwish Rafiq, Oladapo Yeku et al. Nature Biotechnology profile →

Peers

Countries citing papers authored by Terence J. Purdon

Since Specialization

Citations

This map shows the geographic impact of Terence J. Purdon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence J. Purdon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence J. Purdon more than expected).

Fields of papers citing papers by Terence J. Purdon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terence J. Purdon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence J. Purdon. The network helps show where Terence J. Purdon may publish in the future.

Co-authorship network of co-authors of Terence J. Purdon

This figure shows the co-authorship network connecting the top 25 collaborators of Terence J. Purdon. A scholar is included among the top collaborators of Terence J. Purdon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terence J. Purdon. Terence J. Purdon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition 2021 ·Frontiers in Immunology ·Oladapo Yeku,Thapi D. Rao,(unknown),(unknown),Terence J. Purdon,Pei Wang,Ziyou Cui,Hong Liu,Renier J. Brentjens,David R. Spriggs	26
2	Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy 2020 ·Cancer Immunology Research ·Dylan J. Drakes,Sarwish Rafiq,Terence J. Purdon,Andrea V. Lopez,Smita S. Chandran,Christopher A. Klebanoff,Renier J. Brentjens	24
3	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma 2020 ·Blood Cancer Discovery ·Carlos Fernández de Larrea,Mette Stæhr,Andrea V. Lopez,(unknown),Yunxin Chen,(unknown),Terence J. Purdon,Vladimir Ponomarev,Hans-Guido Wendel,Renier J. Brentjens,Eric L. Smith	147
4	Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages 2020 ·Nature Communications ·Mei Song,Oladapo Yeku,Sarwish Rafiq,Terence J. Purdon,Xue Dong,Lijing Zhu,Tuo Zhang,Huan Wang,(unknown),Junhua Mai,Haifa Shen,Briana G. Nixon,Ming O. Li,Renier J. Brentjens,Xiaojing Ma	111
5	Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response 2020 ·Leukemia ·Xinghuo Li,Anthony F. Daniyan,Andrea V. Lopez,Terence J. Purdon,Renier J. Brentjens	50
6	Abstract IA21: MUC16-directed immunotherapy for ovarian cancer 2020 ·Clinical Cancer Research ·Oladapo Yeku,Sarwish Rafiq,Mythili Koneru,Terence J. Purdon,Mei Song,Pei Wang,Ronald C. Hendrickson,Renier J. Brentjens,David R. Spriggs	2
7	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy 2019 ·Cancer Immunology Research ·Eric L. Smith,Sham Mailankody,Mette Stæhr,Xiuyan Wang,Brigitte Sénéchal,Terence J. Purdon,Anthony F. Daniyan,Mark B. Geyer,Aaron D. Goldberg,Elena Mead,Bianca Santomasso,Jonathan Landa,Andreas Rimner,Isabelle Rivière,Ola Landgren,Renier J. Brentjens	67
8	Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL 2019 ·JCI Insight ·Mark B. Geyer,Isabelle Rivière,Brigitte Sénéchal,Xiuyan Wang,Yongzeng Wang,Terence J. Purdon,Meier Hsu,Sean M. Devlin,M. Lia Palomba,Elizabeth Halton,Yvette Bernal,Dayenne G. van Leeuwen,Michel Sadelain,Jae H. Park,Renier J. Brentjens	69
9	CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response 2019 ·Cancer Cell ·Nicholas F. Kuhn,Terence J. Purdon,Dayenne G. van Leeuwen,Andrea V. Lopez,Kevin J. Curran,Anthony F. Daniyan,Renier J. Brentjens	187
10	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivobreakdown → 2018 ·Nature Biotechnology ·Sarwish Rafiq,Oladapo Yeku,(unknown),Terence J. Purdon,Dayenne G. van Leeuwen,Dylan J. Drakes,Mei Song,Matthew M. Miele,Zhuoning Li,Pei Wang,Su Yan,Jingyi Xiang,Xiaojing Ma,Venkatraman Seshan,Ronald C. Hendrickson,Liu C,Renier J. Brentjens	628
11	Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008) 2018 ·Neurology ·Bianca Santomasso,Jae Hong Park,Isabelle Rivière,Elena Mead,Daniel Li,Brigitte Sénéchal,Terence J. Purdon,Elizabeth Halton,Claudia Diamonte,Michel Sadelain,(unknown)	3
12	Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System 2018 ·Cell Reports ·Mauro P. Avanzi,Oladapo Yeku,Xinghuo Li,Dinali Wijewarnasuriya,Dayenne G. van Leeuwen,Kenneth Cheung,H. Park,Terence J. Purdon,Anthony F. Daniyan,Matthew H. Spitzer,Renier J. Brentjens	268
13	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy 2018 ·Molecular Therapy ·Mark B. Geyer,Isabelle Rivière,Brigitte Sénéchal,Xiuyan Wang,Yongzeng Wang,Terence J. Purdon,Meier Hsu,Sean M. Devlin,Elizabeth Halton,Nicole Lamanna,Jürgen Rademaker,Michel Sadelain,Renier J. Brentjens,Jae H. Park	60
14	Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL. 2017 ·Journal of Clinical Oncology ·Jae Hong Park,Bianca Santomasso,Isabelle Rivière,Brigitte Sénéchal,Xiuyan Wang,Terence J. Purdon,Yongzeng Wang,Elizabeth Halton,Claudia Diamonte,Daniel Li,Michel Sadelain,Renier J. Brentjens	20
15	Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen 2016 ·Leukemia ·Sarwish Rafiq,Terence J. Purdon,Anthony F. Daniyan,Mythili Koneru,Tao Dao,(unknown),David A. Scheinberg,Renier J. Brentjens	128
16	Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. 2016 ·Journal of Clinical Oncology ·Mark B. Geyer,Jae Hong Park,Isabelle Rivière,Xiuyan Wang,Terence J. Purdon,Michel Sadelain,Renier J. Brentjens	5
17	Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression 2015 ·Molecular Therapy ·Kevin J. Curran,(unknown),Yan Nikhamin,Raymond Yeh,(unknown),Dayenne G. van Leeuwen,Terence J. Purdon,Hollie J. Pegram,Renier J. Brentjens	188
18	IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo 2015 ·OncoImmunology ·Mythili Koneru,Terence J. Purdon,David R. Spriggs,(unknown),Renier J. Brentjens	361
19	CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL 2014 ·Blood ·Jae H. Park,Isabelle Rivière,Xiuyan Wang,Yvette Bernal,Sarah Yoo,Terence J. Purdon,Elizabeth Halton,(unknown),Kevin J. Curran,Craig S. Sauter,Marco L. Davila,Michel Sadelain,Renier J. Brentjens	17
20	IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia 2014 ·Leukemia ·Hollie J. Pegram,Terence J. Purdon,Dayenne G. van Leeuwen,Kevin J. Curran,Sergio Giralt,Juliet N. Barker,Renier J. Brentjens	126

About Terence J. Purdon

Terence J. Purdon is a scholar working on Oncology, Immunology and Genetics, having authored 41 papers that have together received 3.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (40 papers), Immune Cell Function and Interaction (11 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). The work is most often cited by research in Oncology (2.9k citations), Immunology (1.1k citations) and Genetics (837 citations). Terence J. Purdon has collaborated with scholars based in United States, Switzerland and Netherlands. Frequent co-authors include Renier J. Brentjens, Mythili Koneru, David R. Spriggs, Oladapo Yeku, Dayenne G. van Leeuwen, Anthony F. Daniyan, Kevin J. Curran, Sarwish Rafiq, Andrea V. Lopez and Pei Wang. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact